Because of Brexit, The UK may no longer be part of the European Medicines Agency (EMA), which actually authorizes the drugs that will be released all over EU. Right now, the headquarters for the EMA is located in the UK, but it will not be long before they leave the country.
Independent reports that the former chairman of Medicines and Healthcare products Regulatory Agency (MHRA), Sir Alasdair Breckenridge that the consequence of this move would mean that companies would need to pay for a separate assessment for their product to be used in the country.
This may mean that they would take their time in doing so, resulting in new drugs being delayed by as long as 24 months. The UK might be receiving the drugs two years after it has been introduced to the United States of America, the European Union and Japan.
BBC reports that the vice-president of Eisai, Japanese drugs firm, appeals that the UK should enter into a cooperation deal with the EMA, even if they are no longer part of the EU.
While these concerns were being raised by these professionals, a spokeswoman from the Department of Health says that it is dedicated to making sure that the citizens are able to receive the necessary treatment of effective medicines. "In fact, Brexit brings opportunities in this area, and we will be focused on whether we can secure even faster access to the latest innovations for British patients," says the spokeswoman.
The absence of Jeremy Hunt from the Brexit cabinet may be contributing to the idea that health care is very much needed by the citizens. Philippa Whitford from the Scottish National Party says the issues with health care, such as the insurance card and the pensioner's right to access to heath care in Europe must be brought up.
